Emerging treatment landscape of non-muscle invasive bladder cancer-Reference-Cited by-同舟云学术

Emerging treatment landscape of non-muscle invasive bladder cancer

Published:2022-05-31 Issue:6 Volume:22 Page:717-734
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Valenza Carmine¹²,Antonarelli Gabriele¹²,Giugliano Federica¹²,Aurilio Gaetano³,Verri Elena³,Briganti Alberto⁴,Curigliano Giuseppe¹²^ORCID,Necchi Andrea⁴

Affiliation:

1. Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, Milan, Italy

2. (DIPO), University of MilanDepartment of Oncology and Hemato-Oncology, Milan, Italy

3. Division of Urogenital and Head and Neck Tumours, European Institute of Oncology, Milan, Italy

4. San Raffaele Department of Medical Oncology, IRCCS San Raffaele Hospital and Scientific InstituteUniversity Vita-Salute, Milan, Italy

Funder

The author(s) reported there is no funding associated with the work featured in this article

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2022.2082869

Reference136 articles.

1. WHO - International Agency for Reasearch on Cancer. Globocan [Internet]. 2020 cited 2021 Oct 2. cited 2021 Oct 2: https://gco.iarc.fr/today/data/factsheets/cancers/30-Bladder-fact-sheet.pdf

2. Bladder cancer

3. Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base

4. Epidemiology and Risk Factors of Urothelial Bladder Cancer

5. Bladder cancer: Epidemiology, staging and grading, and diagnosis

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nadofaragene: a new era of precision medicine for bladder cancer;Annals of Medicine & Surgery;2023-11-07

2. Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer;Bladder Cancer;2023-06-27

3. Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies;Cells;2023-06-12

4. ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential;Frontiers in Immunology;2022-11-10

5. Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape;Expert Review of Clinical Pharmacology;2022-11-08